Anti-VEGF agents in the treatment of diabetic macular edema
Diabetic macular edema (DME) is a common complication associated with the loss of visual acuity in diabetic patients. Intravitreal injections of vascular endothelium growth factor (VEGF) inhibitors (anti-VEGF therapy) have been proposed recently as a new treatment option for patients with DME. In th...
Guardado en:
Autores principales: | Vladimir Iosifovich Konenkov, Vadim Valerievich Klimontov, Valeriy Vyacheslavovich Chernykh, Nadezhda Viktorovna Tjan |
---|---|
Formato: | article |
Lenguaje: | EN RU |
Publicado: |
Endocrinology Research Centre
2013
|
Materias: | |
Acceso en línea: | https://doaj.org/article/742d86e339d947eb8af79c385b38765a |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Primary treatment of diabetic macular edema
por: Tushar M Ranchod, et al.
Publicado: (2009) -
Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema: Exploratory Retrospective Analysis
por: Pessoa B, et al.
Publicado: (2021) -
Contralateral eye-to-eye comparison of intravitreal ranibizumab and a sustained-release dexamethasone intravitreal implant in recalcitrant diabetic macular edema
por: Thomas BJ, et al.
Publicado: (2016) -
EFFECT OF ANTI-VEGF THERAPY ON THE STRUCTURAL STATE OF THE RETINA IN DIABETIC MACULAR EDEMA
por: M. M. Bikbov, et al.
Publicado: (2016) -
Managing Diabetic Macular Edema in Clinical Practice: Systematic Review and Meta-Analysis of Current Strategies and Treatment Options
por: Veritti D, et al.
Publicado: (2021)